| Literature DB >> 28532516 |
Peng Chen1, Ruixiang Xu1, Lei Yan2, Zhengrong Wu1, Yan Wei3, Wenbin Zhao1, Xin Wang1, Qinjian Xie3, Hongyu Li4,5.
Abstract
Realgar is a naturally occurring arsenic sulfide (or Xionghuang, in Chinese). It contains over 90% tetra-arsenic tetra-sulfide (As4S4). Currently, realgar has been confirmed the antitumor activities, both in vitro and in vivo, of realgar extracted using Acidithiobacillus ferrooxidans (A. ferrooxidans). Bioleaching, a new technology to greatly improve the use rate of arsenic extraction from realgar using bacteria, is a novel methodology that addressed a limitation of the traditional method for realgar preparation. The present systematic review reports on the research progress in realgar bioleaching and its antitumor mechanism as an anticancer agent. A total of 93 research articles that report on the biological activity of extracts from realgar using bacteria and its preparation were presented in this review. The realgar bioleaching solution (RBS) works by inducing apoptosis when it is used to treat tumor cells in vitro and in vivo. When it is used to treat animal model organisms in vivo, such as mice and Caenorhabditis elegans, tumor tissues grew more slowly, with mass necrosis. Meanwhile, the agent also showed obvious inhibition of tumor cell growth. Bioleaching technology greatly improves the utilization of realgar and is a novel methodology to improve the traditional method.Entities:
Keywords: A. ferrooxidans; Anticancer effect; Bioleaching; RBS; Realgar
Mesh:
Substances:
Year: 2017 PMID: 28532516 PMCID: PMC5441017 DOI: 10.1186/s40659-017-0122-y
Source DB: PubMed Journal: Biol Res ISSN: 0716-9760 Impact factor: 5.612
Fig. 1Bioleaching preparation and anticancer mechanism of realgar
The comparison of pharmacological activities among different arsenic agent in vivo and in vitro
| Types | Models | Parameters | Realgar | NPSf | ATO | RBS | Reference |
|---|---|---|---|---|---|---|---|
| Cell lines | HepG2 | IC50 in 72 h (μg/ml) | NDa | NDa | 0.58 ± 0.08 | 0.43 ± 0.06 | [ |
| H22 | Apoptotic rateb (%) | NDa | NDa | 12.8 | 15.8 | [ | |
| H22 | IC50 at 72 h (µM) | 104.36 | 34.27 | NDa | NDa | [ | |
| H22 | AUC0→24 (ng h/l) | 1282.28 ± 586.23 | 4796.25 ± 479.885 | NDa | NDa | [ | |
| H22 | t½ (h) | 44.9 ± 18.1 | 53.3 ± 44.9 | NDa | NDa | [ | |
| H22 | Biodistributionc (ng/g) | 320 | 610 | NDa | NDa | [ | |
| SiHa cells | Toxicity (g/kg) | 3.2 | NDa | 0.033–0.039 | NDa | [ | |
| SiHa cells | Bioavailability rate (%) | 4% | NDa | High | NDa | [ | |
| C6 | Apoptotic rate (%) | 4.73% ± 0.46 | 26.02 ± 0.28 | ND | NDa | [ | |
| HeLa | IC50 at 72 h (µM) | 8.69 ± 2.57 | NDa | 1.85 ± 0.54 | NDa | [ | |
| ECV-304 | Toxic | More | Less | NDa | NDa | [ | |
| ECV-304 | Bioavailability | Low | High | NDa | NDa | [ | |
| B16 | Apoptotic rate (%) | NDa | 11.4–54.95 | ND.a | ND.a | [ | |
| B16 | Inhibitory rated (%) | NDa | NDa | 22.70 | 27.0 | [ | |
| B16 | Accumulating rate (%) | ND.a | NDa | 36.6 | 71.50 | [ | |
| B16 | t½ (h) | 8.09 ± 2.27 | 10.13 ± 3.19 | NDa | NDa | [ | |
|
| MT2124 | LC50 (μg/mg) | ND | NDa | 55 | 81 | [ |
| S180-bearing | Inhibition rate (%) | 39.5 | 53.14 | NDa | NDa | [ | |
| H22-bearing | Inhibitory rate (%) | NDa | NDa | 41.87 | 42.78 | [ | |
| Mice | H22-bearing | Extending ratese (%) | NDa | NDa | 91.96 | 118.80 | [ |
| Healthy mice | LD50 (g/kg) | 3.2 | NDa | 0.033–0.039 | NDa | [ | |
| Healthy mice | Bioavailability rate (%) | 4% | NDa | NDa | NDa | [ |
ND no data
aThe figures is not given in the paper
bThe percentage of the apoptotic cells
cThe arsenic accumulation in tumor
dThe cancer cells growth inhibitory rate
eThe mice life extending rate
fRealgar nanometer particles
Fig. 2The mechanism of antitumor effect of RBS